Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ADAM proteases, ErbB pathways and cancer.

Bin-Bing S Zhou1, Jordan S Fridman, Xiangdong Liu

  • 1Drug Discovery Biology, Incyte Corporation, Experimental Station, Route 141 & Henry Clay Road, Building 400, Wilmington, DE 19880, USA. bzhou@incyte.com

Expert Opinion on Investigational Drugs
|July 12, 2005
PubMed
Summary

A disintegrin and metalloproteases (ADAMs) are key enzymes in cancer, shedding growth factors in the ErbB pathway. Targeting ADAMs offers a novel therapeutic strategy to complement existing anti-ErbB cancer treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two Chinese patients with Basilicata-Akhtar syndrome caused by novel <i>MSL3</i> variants: a case report and literature review.

Translational pediatrics·2025
Same author

DNA damage response and its clinical implications in pediatric cancers.

DNA repair·2025
Same author

Therapeutic targeting de novo purine biosynthesis driven by β-catenin-dependent PPAT upregulation in hepatoblastoma.

Cell death & disease·2025
Same author

Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers.

Acta pharmacologica Sinica·2024
Same author

Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerability.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2024
Same author

Up-regulation of ABCG1 is associated with methotrexate resistance in acute lymphoblastic leukemia cells.

Frontiers in pharmacology·2024

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • A disintegrin and metalloproteases (ADAMs) are zinc-dependent metalloproteases.
  • ADAMs function as sheddases for membrane-bound proteins, including growth factors, cytokines, and receptors.
  • The ErbB signaling pathway is a crucial regulator of cell proliferation and a validated target in cancer therapy.

Purpose of the Study:

  • To highlight the role of ADAMs as sheddases of ErbB ligands.
  • To identify ADAMs as potential novel drug targets within the ErbB pathway.
  • To explore the therapeutic potential of targeting ADAMs in cancer treatment.

Main Methods:

  • Review of existing literature on ADAMs and ErbB signaling.
  • Analysis of the functional roles of ADAMs in cancer-related processes.

Related Experiment Videos

  • Identification of ADAMs as upstream activators of ErbB ligands.

    • Main Results:

    • ADAMs play a critical role in shedding multiple ErbB ligands, thereby regulating ErbB signaling.
    • ADAMs are implicated in key oncogenic processes including tumor cell proliferation, angiogenesis, and metastasis.
    • The identification of ADAMs as sheddases positions them as critical upstream regulators of the ErbB pathway.

    Conclusions:

    • ADAMs are crucial regulators of ErbB signaling and are involved in multiple aspects of cancer progression.
    • Targeting ADAMs represents a promising therapeutic strategy that could complement existing anti-ErbB treatments.
    • Further research into ADAM-targeted therapies may lead to novel approaches for cancer treatment.